carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper-02', 'atezo', 'tiragolumab', 'sclc']
#asco22 dr. presents the results from skyscraper-02, a double blind phase iii study of carboplatin, etoposide, atezolizumab (imp133 backbone) +/- the anti #tigit antibody tiragolumab for pts with extensive stage #sclc. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him